The purpose of this research study is to test an experimental drug called ORMD-0801, an orally administered form of insulin. The study will evaluate the safety and effect of the medication on blood glucose and A1C levels compared to a matching placebo
Study Duration: 34 weeks/9 office visits (less than 9months). Visits will last between 1-2hrs
Compensation: $75 per completed visits Total of $675
- Male and female subjects aged ≥ 50 years
- Type 2 Diabetes for at least 6 months
- On a stable dose of at least one and up to three of the following glucose-lowering agents: Metformin, sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor, thiazolidinedione, insulin secretagogue, oral or injected GLP-1 receptor agonists, glucosidase inhibitor, or pramlintide (injected insulin is excluded)
- History of use of any injectable insulin (greater than 7 days) within 6 months prior to screening is exclusionary